OfficeLink Updates - October 2026 notices and reminders (PDF)
Already effective September 1 and October 1, 2026, Aetna requires precertification for drugs including Lytenava, Tudriqev, Genglycos, Pasatru, Zanvastro, and Elzonris, and requires Site of Care review for Zimrixby, Jobevne, and Avzivi. Precertification is no longer required for commercial members for OrthoVisc, Zarxio, several bortezomib products, and Fusilev, and it is no longer required for Medicare for several bortezomib products and Fusilev. Effective January 1, 2027, trauma response charges reported with revenue codes 0681 through 0684 will be denied unless a paid HCPCS code G0390 and a paid qualifying ambulance transport charge are billed on the same date of service.